Targovax ASA (Targovax) will release its Q3 2015 results on Thursday November 26, 2015 at 07:00 CET. The quarterly report and the presentation material will be available at this time at www.circio.com.
A presentation of the results will be held at 10:00 CET at Hotel Continental Conference Center, Stortingsgaten 24/26, Oslo, Norway.
CEO Gunnar Gårdemyr, CFO Øystein Soug and CMO Magnus Jäderberg will be representing the company.
Following the quarterly presentation Dr. Jäderberg will give a 20-30 minute presentation on the history of cancer treatments and immunotherapy.
At 14:00 CET (08:00 EST) the same day, Targovax will host a telephone conference, including a presentation of the results, following with a Q&A session. Call in details below.
Please make sure to dial in at least 5-10 minutes ahead of time to complete your registration.
Participant information:
Call in number:
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077
See attached list for more dial in numbers.
http://wpc.1726.planetstream.net/001726/FEL_Events_International_Access_List.pdf
Access code:
68554865#
For further information, please contact:
Øystein Soug
Chief Financial Officer
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
About Targovax
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aim to become a leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology:
Oncos 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment may reinstate the immune system’s capacity to recognize and attack cancer cells.
TG01 is a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers and 20-30% of all cancers. Targovax works towards demonstrating that TG01 will prolong time to cancer progression, increase survival and improve safety and tolerability.
The product candidates will be developed in combination with multiple treatments in several cancer indications, including checkpoint inhibitors. Targovax also has a number of other cancer immune therapy candidates in the early stage of development. For more information visit www.circio.com.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.